Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker

Prostate cancer is responsible for hundreds of thousands of annual deaths worldwide. The current gold standard in early detection of prostate cancer, the prostate specific antigen test, boasts a high sensitivity but low specificity, resulting in many unnecessary prostate biopsies. Thus, emphasis has...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Rachel A., Lund, Maria E., Truong, Quach, Wu, Angela, Shore, Neal D., Saltzstein, Daniel R., Concepcion, Raoul S., Paivanas, Thomas A., van Breda, Arletta, Beebe-Dimmer, Jennifer, Ruterbusch, Julie J., Wissmueller, Sandra, Campbell, Douglas H., Walsh, Bradley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976470/
https://www.ncbi.nlm.nih.gov/pubmed/29854284
http://dx.doi.org/10.18632/oncotarget.25009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976470/
https://www.ncbi.nlm.nih.gov/pubmed/29854284
http://dx.doi.org/10.18632/oncotarget.25009

Ejemplares similares